SLC38A2 and glutamine signalling in cDC1s dictate anti-tumour immunity.

ABSTRACT: Cancer cells evade T cell-mediated killing through tumour-immune interactions whose mechanisms are not well understood^1,2. Dendritic cells (DCs), especially type-1 conventional DCs (cDC1s), mediate T cell priming and therapeutic efficacy against tumours³. DC functions are orchestrated by pattern recognition receptors^3-5, although other signals involved remain incompletely defined. Nutrients are emerging mediators of adaptive immunity^6-8, but whether nutrients affect DC function or communication between innate and adaptive immune cells is largely unresolved. Here we establish glutamine as an intercellular metabolic checkpoint that dictates tumour-cDC1 crosstalk and licenses cDC1 function in activating cytotoxic T cells. Intratumoral glutamine supp

SUBMITTER: Guo C 

PROVIDER: S-EPMC10396969 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature